Effect of the botanical compound LCS101 on chemotherapy-induced symptoms in patients with breast cancer: A case series report

Noah Samuels, Yair Maimon*, Rrachel Y. Zisk-Rrony

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    5 Scopus citations

    Abstract

    The treatment of breast cancer invariably results in severe and often debilitating symptoms that can cause significant distress and severely impair daily function and quality-of-life (QOL). We treated a series of 20 female breast cancer patients with the botanical compound LCS101 as adjuvant to conventional chemotherapy. At the end of the treatment regimen, patients rated their symptoms. 70% reported that they had either no or mildly severe levels of fatigue; 60% none to mildly severe weakness; 85% none to mildly severe pain; 70% none to mildly severe nausea; and 80% none to mildly severe vomiting. Only 20% reported severe impairment of overall function, and only 40% severely impaired QOL. No toxic effects were attributed by patients to the LCS101 treatment, and 85% reported that they believed the botanical compound had helped reduce symptoms. The effects of LCS101 on clinical outcomes in breast cancer should be tested further using randomized controlled trials.

    Original languageAmerican English
    Pages (from-to)1-8
    Number of pages8
    JournalIntegrative Medicine Insights
    Volume2012
    Issue number8
    DOIs
    StatePublished - 2012

    Keywords

    • Botanical compounds
    • Breast cancer
    • Fatigue
    • Nausea and vomiting
    • Pain
    • Quality-of-life

    Fingerprint

    Dive into the research topics of 'Effect of the botanical compound LCS101 on chemotherapy-induced symptoms in patients with breast cancer: A case series report'. Together they form a unique fingerprint.

    Cite this